Logo image of KPTI

KARYOPHARM THERAPEUTICS INC (KPTI) Stock Fundamental Analysis

NASDAQ:KPTI - Nasdaq - US48576U2050 - Common Stock - Currency: USD

6.01  -0.14 (-2.28%)

Fundamental Rating

2

KPTI gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 563 industry peers in the Biotechnology industry. KPTI has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, KPTI is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year KPTI has reported negative net income.
KPTI had a negative operating cash flow in the past year.
In the past 5 years KPTI always reported negative net income.
KPTI had a negative operating cash flow in each of the past 5 years.
KPTI Yearly Net Income VS EBIT VS OCF VS FCFKPTI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

KPTI has a Return On Assets of -46.48%. This is comparable to the rest of the industry: KPTI outperforms 49.56% of its industry peers.
Industry RankSector Rank
ROA -46.48%
ROE N/A
ROIC N/A
ROA(3y)-50.71%
ROA(5y)-51.1%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KPTI Yearly ROA, ROE, ROICKPTI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 -400 600 800

1.3 Margins

The Gross Margin of KPTI (95.86%) is better than 94.32% of its industry peers.
KPTI's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for KPTI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 95.86%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.86%
GM growth 5Y0.37%
KPTI Yearly Profit, Operating, Gross MarginsKPTI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K -50K

More info and screens

1

2. Health

2.1 Basic Checks

KPTI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, KPTI has more shares outstanding
KPTI has less shares outstanding than it did 5 years ago.
KPTI has a worse debt/assets ratio than last year.
KPTI Yearly Shares OutstandingKPTI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
KPTI Yearly Total Debt VS Total AssetsKPTI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

KPTI has an Altman-Z score of -14.27. This is a bad value and indicates that KPTI is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -14.27, KPTI is doing worse than 80.64% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -14.27
ROIC/WACCN/A
WACC6.52%
KPTI Yearly LT Debt VS Equity VS FCFKPTI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 1.70 indicates that KPTI should not have too much problems paying its short term obligations.
KPTI's Current ratio of 1.70 is on the low side compared to the rest of the industry. KPTI is outperformed by 80.28% of its industry peers.
A Quick Ratio of 1.64 indicates that KPTI should not have too much problems paying its short term obligations.
KPTI has a worse Quick ratio (1.64) than 79.57% of its industry peers.
Industry RankSector Rank
Current Ratio 1.7
Quick Ratio 1.64
KPTI Yearly Current Assets VS Current LiabilitesKPTI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

6

3. Growth

3.1 Past

KPTI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 46.40%, which is quite impressive.
Looking at the last year, KPTI shows a decrease in Revenue. The Revenue has decreased by -0.55% in the last year.
KPTI shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 28.85% yearly.
EPS 1Y (TTM)46.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)-0.55%
Revenue growth 3Y-11.54%
Revenue growth 5Y28.85%
Sales Q2Q%-9.5%

3.2 Future

The Earnings Per Share is expected to grow by 17.21% on average over the next years. This is quite good.
Based on estimates for the next years, KPTI will show a very strong growth in Revenue. The Revenue will grow by 24.35% on average per year.
EPS Next Y-45.56%
EPS Next 2Y-1.18%
EPS Next 3Y9.8%
EPS Next 5Y17.21%
Revenue Next Year-0.16%
Revenue Next 2Y7.75%
Revenue Next 3Y15.11%
Revenue Next 5Y24.35%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
KPTI Yearly Revenue VS EstimatesKPTI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M
KPTI Yearly EPS VS EstimatesKPTI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -10 -20 -30 -40 -50

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for KPTI. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KPTI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KPTI Price Earnings VS Forward Price EarningsKPTI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KPTI Per share dataKPTI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 -20

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.18%
EPS Next 3Y9.8%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for KPTI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KARYOPHARM THERAPEUTICS INC

NASDAQ:KPTI (5/9/2025, 8:04:50 PM)

6.01

-0.14 (-2.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-06 2025-05-06/bmo
Earnings (Next)08-04 2025-08-04/bmo
Inst Owners49.37%
Inst Owner Change-6.58%
Ins Owners0.81%
Ins Owner Change0.81%
Market Cap51.51M
Analysts83.08
Price Target49.62 (725.62%)
Short Float %22.9%
Short Ratio5.6
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.51%
Min EPS beat(2)3.03%
Max EPS beat(2)10%
EPS beat(4)3
Avg EPS beat(4)-114.42%
Min EPS beat(4)-1309.54%
Max EPS beat(4)838.82%
EPS beat(8)3
Avg EPS beat(8)-723.38%
EPS beat(12)3
Avg EPS beat(12)-918.61%
EPS beat(16)4
Avg EPS beat(16)-862.8%
Revenue beat(2)1
Avg Revenue beat(2)-6.75%
Min Revenue beat(2)-14.12%
Max Revenue beat(2)0.62%
Revenue beat(4)2
Avg Revenue beat(4)-0.84%
Min Revenue beat(4)-14.12%
Max Revenue beat(4)15.94%
Revenue beat(8)4
Avg Revenue beat(8)-1.16%
Revenue beat(12)7
Avg Revenue beat(12)2.76%
Revenue beat(16)9
Avg Revenue beat(16)16.41%
PT rev (1m)-14.91%
PT rev (3m)987.3%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1508.01%
EPS NY rev (1m)0%
EPS NY rev (3m)-1895.86%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.1%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-7%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.35
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-10.05
EYN/A
EPS(NY)-14.63
Fwd EYN/A
FCF(TTM)-14.89
FCFYN/A
OCF(TTM)-14.88
OCFYN/A
SpS16.95
BVpS-21.71
TBVpS-21.71
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -46.48%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 95.86%
FCFM N/A
ROA(3y)-50.71%
ROA(5y)-51.1%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.86%
GM growth 5Y0.37%
F-Score2
Asset Turnover0.88
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 41.76%
Cap/Sales 0.1%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.7
Quick Ratio 1.64
Altman-Z -14.27
F-Score2
WACC6.52%
ROIC/WACCN/A
Cap/Depr(3y)20.37%
Cap/Depr(5y)20.63%
Cap/Sales(3y)0.06%
Cap/Sales(5y)0.08%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)46.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
EPS Next Y-45.56%
EPS Next 2Y-1.18%
EPS Next 3Y9.8%
EPS Next 5Y17.21%
Revenue 1Y (TTM)-0.55%
Revenue growth 3Y-11.54%
Revenue growth 5Y28.85%
Sales Q2Q%-9.5%
Revenue Next Year-0.16%
Revenue Next 2Y7.75%
Revenue Next 3Y15.11%
Revenue Next 5Y24.35%
EBIT growth 1Y7.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-12.18%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-37.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-37.49%
OCF growth 3YN/A
OCF growth 5YN/A